ArticleClinical drug investigation2016
Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database.
Article in Clinical drug investigation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Abuse and Misuse of Pregabalin and Gabapentin.Drugs · 2017Pooled it
- A hospital-based multi-centric observational study to explore the prevalence and correlates of non-medical use and dependence of pregabalin among the patients with substance use disorder in Punjab & Chandigarh.Substance abuse treatment, prevention, and policy · 2026Observational
- Pregabalin dependence, withdrawal, suicidality and psychosis reports: A disproportionality analysis of the Australian adverse events database.British journal of clinical pharmacology · 2026Article
- Prevalence of and Factors Associated with Gabapentinoid Use and Misuse Among Texas Medicaid Recipients.Clinical drug investigation · 2021Article
- Gabapentinoid Abuse in France: Evidence on Health Consequences and New Points of Vigilance.Frontiers in psychiatry · 2021Article
- Assessment of the Safety Signal for the Abuse Potential of Pregabalin and Gabapentin Using the FAERS Database and Big Data Search Analytics.Frontiers in psychiatry · 2021Article
- Gabapentinoid Benefit and Risk Stratification: Mechanisms Over Myth.Pain and therapy · 2020Review
- Current Evidence on Abuse and Misuse of Gabapentinoids.Drug safety · 2020Review
- Pregabalin induced visual hallucinations - a rare adverse reaction.BMC pharmacology & toxicology · 2020Article
- Comment on: An Insight Into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions.The international journal of neuropsychopharmacology · 2019Article
- Lack of correlation between the activity of the mesolimbic dopaminergic system and the rewarding properties of pregabalin in mouse.Psychopharmacology · 2019Article
- Patterns of gabapentin and pregabalin use and misuse: Results of a population-based cohort study in France.British journal of clinical pharmacology · 2019Observational
- Identification of Somatic Disorders Related to Psychoactive Drug Use from an Inpatient Database in a French University Hospital.Clinical drug investigation · 2018Article
- Pregabalin dispensing patterns in Amman-Jordan: An observational study from community pharmacies.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2018Article
- Early signal of diverted use of tropicamide eye drops in France.British journal of clinical pharmacology · 2017Article
- Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?Clinical drug investigation · 2017Review
- Sensitivity of Quantitative Signal Detection in Regards to Pharmacological Neuroenhancement.International journal of molecular sciences · 2017Article
- Pregabalin for the Treatment of Drug and Alcohol Withdrawal Symptoms: A Comprehensive Review.CNS drugs · 2016Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivePregabalin abuse and dependence has been increasingly described; however, it is not described in France. Our study aimed to investigate the abuse and dependence potential of pregabalin by a disproportionality analysis, in the French Pharmacovigilance Database (FPVD), in comparison with amitriptyline and clonazepam.
methodsWe performed a case/noncase study in the FPVD. Between January, 1 2010 and December, 31 2015, we identified cases of abuse and or dependence (excluding isolated withdrawal syndromes) using MedDRA (Medical Dictionary for Regular Activities) terms. Exposure to pregabalin was defined as the mention of pregabalin in the report. Clonazepam was used as positive control and amitriptyline as negative control.
resultsAmong the 184,310 reports in the database, 521 were abuse or dependence cases. Exposure to pregabalin was found in eight (1.5 %) of them. We did not find any significant association between exposure to pregabalin and drug abuse or dependence: reporting odds ratio (ROR) = 1.1 95 % confidence interval (CI) (0.6-2.3). ROR for clonazepam was 5.7 95 % CI (3.5-9.2). No case of an amitriptyline-related abuse or dependence was recorded in the FPVD.
conclusionsThe first cases of pregabalin-related abuse or dependence reported in France occurred later than in other European countries, since none had been described before 2010. This analysis in the FPVD did not find a higher proportion of abuse/dependence with pregabalin in comparison with other drugs. Considering evidence of pregabalin abuse worldwide, this analysis underlines the limitations of spontaneous reporting system in the field of addictovigilance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.